RxDoctor Payments Data

Shannon Miller, APRN

Family · Oklahoma City, OKNPI 1063850766

Payments from drug & device makers

$2,166in general payments, 2019–2025

Across 133 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$438
  • GSK$431
  • AstraZeneca$227
  • Lilly USA, LLC$221
  • Pfizer$177
  • Dexcom, Inc.$127
  • plus $545 from 15 others

What the payments were for

  • Food & beverage$2,166100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,166 in reported general payments places this provider in the 80th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$41,858
Medicare patients
153
Services billed
970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$81,805
MounjaroTirzepatide38$45,653
TrulicityDulaglutide24$33,350
EliquisApixaban19$25,746
MyrbetriqMirabegron38$24,939
ProliaDenosumab13$23,211
FarxigaDapagliflozin Propanediol13$22,148
JardianceEmpagliflozin12$21,180
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,161
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,340
Breo ElliptaFluticasone/Vilanterol14$5,217
Dexlansoprazole DrDexlansoprazole14$5,048
Atorvastatin Calcium334$3,591
Levothyroxine Sodium292$2,763
Albuterol Sulfate HfaAlbuterol Sulfate93$2,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$109$81,80566 claims
Lilly USA, LLCMounjaro, Trulicity$221$79,00262 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$431$29,71855 claims
PfizerEliquis$177$25,74619 claims
Astellas Pharma US IncMyrbetriq$59$24,93938 claims
AmgenProlia$31$23,21113 claims
AstraZenecaFarxiga$227$22,14813 claims
Boehringer IngelheimJardiance$29$21,18012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,026 family providers in Oklahoma.

Other family in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →